SynonymsBot
Synonyms for fluzone or Related words with fluzone
vaxigrip
fluvirin
unadjuvanted
agrippal
flulaval
fluarix
engerix
boostrix
fluviral
tetravac
menveo
acthib
fluad
rmomp
menactra
fluvax
pneumovax
pediarix
tdap
circoflex
aggripal
raboral
protollin
imovax
pentavac
rabipur
omvsbp
adacel
adjuvanted
acwy
laiv
begrivac
pentacel
meningitect
fluoropeptide
menomune
dryvax
kinrix
adjuvantfluarix
aidsvax
encepur
thevaccine
bacterin
dmlt
denvax
zostavax
hiberix
ingelvac
daptacel
stamaril
Examples of "fluzone"
The use of
Fluzone
in infants less than six months of age is not recommended. Immunization with
Fluzone
may not protect 100% of susceptible individuals.
Fluzone
is typically administered in a single dose by intramuscular injection; an intradermal injection is also available. It is presented as a 0.25 ml syringe for pediatric use, as a 0.5 ml syringe for adults and children, as a 0.5 ml vial for adults and children, and as a 5 ml vial for adults and children.
Fluzone
must be refrigerated under temperatures from and is inactivated by freezing.
Fluzone
was initially approved in 1980 by the FDA.
In January 2011 the FDA recognized that 36 children from 6–24 months old had fevers and seizures within a day of the
fluzone
vaccine.
In several preclinical trials, Global Vaccines' novel technologies have already shown remarkable promise across a range of disease targets.
Fluzone
is a brand of influenza vaccine, distributed by Sanofi Pasteur. It is a split-virus vaccine that is produced by chemical disruption of the influenza virus. Therefore, it is incapable of causing influenza.
Fluzone
comes in three versions that are thimerosal-free. There is a 0.25 ml prefilled pediatric syringe, a 0.5 ml prefilled syringe, and a 0.5 ml vial. Thimerosal is used only in the 5 ml multi-use vial.
A high-dose vaccine (
Fluzone
High-Dose) 4x the strength of standard flu vaccine was approved by the FDA in 2009. This vaccine is intended for people 65 and over, who typically have weakened immune response due to normal aging. The vaccine produces a greater immune response than standard vaccine. According to the CDC, "a study published in the New England Journal of Medicine [in August, 2014] indicated that the high-dose vaccine was 24.2% more effective in preventing flu in adults 65 years of age and older relative to a standard-dose vaccine." CDC recommends the high-dose vaccine for people 65 and over but expresses no preference between it and standard vaccine. Further studies are underway.